Education
About Us
Working with TipRanks
Follow Us
Natera Inc. (NTRA)
:NTRA
NTRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$100.22 - $183.00
Previous CloseN/A
Volume352.74K
Average Volume (3M)1.28M
Market Cap
$19.13B
Enterprise Value$18.26B
Total Cash (Recent Filing)$991.60M
Total Debt (Recent Filing)$195.60M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 05, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding136,546,590
10 Day Avg. Volume1,381,274
30 Day Avg. Volume1,282,476
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue9.97
Enterprise Value/Gross Profit16.13
Enterprise Value/Ebitda-123.69
Forecast
1Y Price Target
$201.56Price Target Upside43.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
EarningsAnalyst reiterates confidence in NTRA as a top pick for earnings, expecting a strong beat on revenue and Signatera volumes.
Growth PotentialNTRA remains the front-runner in the $20B MRD market, with strong unit volume growth and continued momentum of Signatera.
Market PositionSignatera maintains its dominant position in MRD, growing clinical tests sequentially and having over 90% market share, with plenty of room for additional growth.
Bears Say
CompetitionNew entrants are rapidly entering the MRD market, aiming to capture a share of this large opportunity, increasing competition for NTRA.
Data LimitationsWGS Signatera poster lacks landmark CRC data, which is considered an important benchmark.
Operating ExpensesRecent sell-off in NTRA shares has led to increased investor inquiries about potential increases in operating expenses and emerging competition.
Natera News
NTRA FAQ
What was Natera Inc.’s price range in the past 12 months?
Natera Inc. lowest stock price was $100.22 and its highest was $183.00 in the past 12 months.
What is Natera Inc.’s market cap?
Natera Inc.’s market cap is $19.13B.
When is Natera Inc.’s upcoming earnings report date?
Natera Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.
How were Natera Inc.’s earnings last quarter?
Natera Inc. released its earnings results on Aug 07, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.615 by -$0.125.
Is Natera Inc. overvalued?
According to Wall Street analysts Natera Inc.’s price is currently Undervalued.
Does Natera Inc. pay dividends?
Natera Inc. does not currently pay dividends.
What is Natera Inc.’s EPS estimate?
Natera Inc.’s EPS estimate is -0.56.
How many shares outstanding does Natera Inc. have?
Natera Inc. has 136,546,590 shares outstanding.
What happened to Natera Inc.’s price movement after its last earnings report?
Natera Inc. reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.615. Following the earnings report the stock price went down -6.533%.
Which hedge fund is a major shareholder of Natera Inc.?
Currently, no hedge funds are holding shares in NTRA
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$201.56 (43.85% Upside)
$201.56 (43.85% Upside)
Blogger Sentiment
Neutral
NTRA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 37.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.87%
12-Months-Change
Fundamentals
Return on Equity
-18.66%
Trailing 12-Months
Asset Growth
17.99%
Trailing 12-Months
Company Description
Natera Inc.
Natera, Inc. (NTRA) is a global leader in cell-free DNA testing, dedicated to improving patient care and reducing healthcare costs through genetic testing solutions. The company operates primarily in the biotechnology and medical diagnostics sectors, offering a range of tests that provide critical insights into genetic health. Natera's core products include non-invasive prenatal testing (NIPT), organ transplant rejection assessments, and oncology diagnostics, which help in early disease detection and management.
NTRA Company Deck
NTRA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance for Natera, with significant revenue growth, volume increases across key segments, and positive cash flow. Despite minor challenges such as weather disruptions and some uncertainty in ASP improvements, the company's strategic initiatives in diagnostics and oncology are bearing fruit, leading to an optimistic outlook.View all NTRA earnings summariesNTRA Stock 12 Month Forecast
Average Price Target
$201.56
▲(43.85% Upside)
Technical Analysis
Ownership Overview
4.69% Insiders
29.80% Mutual Funds
0.65% Other Institutional Investors
49.15% Public Companies and
Individual Investors